Petros Pharmaceuticals (PTPI) Competitors $0.03 0.00 (-7.14%) As of 03:02 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PTPI vs. BDRX, RDHL, ARTL, QLGN, ENVB, INDP, GTBP, LIPO, PRFX, and VAXXShould you be buying Petros Pharmaceuticals stock or one of its competitors? The main competitors of Petros Pharmaceuticals include Biodexa Pharmaceuticals (BDRX), Redhill Biopharma (RDHL), Artelo Biosciences (ARTL), Qualigen Therapeutics (QLGN), Enveric Biosciences (ENVB), Indaptus Therapeutics (INDP), GT Biopharma (GTBP), Lipella Pharmaceuticals (LIPO), PainReform (PRFX), and Vaxxinity (VAXX). These companies are all part of the "pharmaceutical products" industry. Petros Pharmaceuticals vs. Its Competitors Biodexa Pharmaceuticals Redhill Biopharma Artelo Biosciences Qualigen Therapeutics Enveric Biosciences Indaptus Therapeutics GT Biopharma Lipella Pharmaceuticals PainReform Vaxxinity Biodexa Pharmaceuticals (NASDAQ:BDRX) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership. Which has more risk and volatility, BDRX or PTPI? Biodexa Pharmaceuticals has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500. Do institutionals and insiders have more ownership in BDRX or PTPI? 17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are held by insiders. Comparatively, 8.2% of Petros Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is BDRX or PTPI more profitable? Biodexa Pharmaceuticals' return on equity of 0.00% beat Petros Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Biodexa PharmaceuticalsN/A N/A N/A Petros Pharmaceuticals N/A -78.22%-23.50% Which has preferable earnings & valuation, BDRX or PTPI? Biodexa Pharmaceuticals has higher earnings, but lower revenue than Petros Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiodexa Pharmaceuticals$470K8.26-$7.32MN/AN/APetros Pharmaceuticals$5.11M0.16-$8.16M-$52.910.00 Does the media refer more to BDRX or PTPI? In the previous week, Biodexa Pharmaceuticals had 5 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 5 mentions for Biodexa Pharmaceuticals and 0 mentions for Petros Pharmaceuticals. Biodexa Pharmaceuticals' average media sentiment score of 0.78 beat Petros Pharmaceuticals' score of 0.00 indicating that Biodexa Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Biodexa Pharmaceuticals Positive Petros Pharmaceuticals Neutral SummaryBiodexa Pharmaceuticals beats Petros Pharmaceuticals on 7 of the 10 factors compared between the two stocks. Get Petros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PTPI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PTPI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTPI vs. The Competition Export to ExcelMetricPetros PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$810K$850.45M$5.73B$10.31BDividend YieldN/A4.84%5.90%4.63%P/E Ratio-0.011.1057.1222.76Price / Sales0.1626.62528.74123.58Price / CashN/A19.5637.1760.46Price / Book0.016.5812.796.29Net Income-$8.16M-$4.18M$3.28B$270.51M7 Day PerformanceN/A2.39%0.22%2.15%1 Month PerformanceN/A7.86%4.61%6.35%1 Year PerformanceN/A23.73%68.33%25.48% Petros Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTPIPetros Pharmaceuticals0.1782 of 5 stars$0.03-7.1%N/A-99.7%$810K$5.11M-0.0120Gap DownBDRXBiodexa Pharmaceuticals0.5637 of 5 stars$5.36+0.7%N/AN/A$3.32M$470K0.0020Short Interest ↓Gap DownRDHLRedhill BiopharmaN/A$1.43-0.7%N/A-86.4%$3.28M$8.04M0.00210Short Interest ↑ARTLArtelo Biosciences3.0436 of 5 stars$4.67+2.6%$24.00+413.9%-25.8%$3.27MN/A-0.255Short Interest ↓QLGNQualigen TherapeuticsN/A$1.72-0.6%N/A-75.3%$2.92M$4.98M0.0050News CoverageENVBEnveric Biosciences2.2552 of 5 stars$0.89-1.6%$10.00+1,029.9%-87.5%$2.88MN/A-0.0220News CoverageShort Interest ↑INDPIndaptus Therapeutics3.5881 of 5 stars$2.55-12.5%$238.00+9,251.7%-94.6%$2.83MN/A-0.076Positive NewsShort Interest ↓GTBPGT Biopharma2.6663 of 5 stars$0.78-9.0%$11.00+1,303.1%-63.3%$2.79MN/A-0.198Short Interest ↓Gap DownLIPOLipella Pharmaceuticals2.015 of 5 stars$0.59-2.3%N/A-81.4%$2.71M$536.36K-0.144News CoverageNegative NewsShort Interest ↓PRFXPainReform0.742 of 5 stars$1.34-4.0%N/A-61.5%$2.68MN/A-0.014Short Interest ↑Gap DownVAXXVaxxinityN/A$0.02-50.0%N/A-95.0%$2.54MN/A-0.0490Gap Down Related Companies and Tools Related Companies Biodexa Pharmaceuticals Competitors Redhill Biopharma Competitors Artelo Biosciences Competitors Qualigen Therapeutics Competitors Enveric Biosciences Competitors Indaptus Therapeutics Competitors GT Biopharma Competitors Lipella Pharmaceuticals Competitors PainReform Competitors Vaxxinity Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTPI) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Petros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Petros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PTPI Stock Alerts